Pharmaceuticals

Global Angiotensin Receptor Blockers (ARBs) Market Performance Report: Global Trends 2026–2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the angiotensin receptor blockers (arbs) market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Angiotensin Receptor Blockers (ARBs) Market in 2026, and what figure is it projected to hit by 2030?

The market size for angiotensin receptor blockers (arbs) has demonstrated consistent expansion in recent years. This market is anticipated to expand from $8.78 billion in 2025 to $9.18 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.6%. Its historical growth can be attributed to the rising prevalence of hypertension, growing awareness of cardiovascular diseases, the expansion of hospital networks, the introduction of new arb molecules, and increasing research in kidney disease treatments.

The angiotensin receptor blockers (arbs) market is projected to experience consistent growth in the coming years, with its size anticipated to reach $11.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.7%. This expansion during the forecast period is primarily driven by factors such as an aging population, the increasing demand for personalized medicine, innovations in drug delivery technologies, a rise in healthcare spending, and the proliferation of specialty clinics. Significant trends anticipated within this period encompass personalized approaches to hypertension management, advancements in treatments for chronic kidney disease, an increase in cardiovascular disease therapies, the broader adoption of oral arb formulations, and a surge in prescriptions from hospitals and specialty clinics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

Which Drivers Are Affecting Market Participation In The Angiotensin Receptor Blockers (ARBs) Market?

The growing occurrence of cardiovascular diseases is anticipated to drive the expansion of the angiotensin receptor blockers market in the coming years. Cardiovascular disease (CVD) refers to any ailment affecting the heart or blood vessels, frequently linked to the accumulation of fatty deposits in arteries (atherosclerosis) and an elevated chance of blood clots. Angiotensin receptor blockers facilitate vein and artery relaxation, thereby lowering blood pressure and enhancing the heart’s pumping efficiency, which helps to reduce the risk of cardiovascular disease. For example, in January 2024, data from the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted death rate due to cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the rising incidence of cardiovascular diseases is boosting the growth of the angiotensin receptor blockers market. The increasing prevalence of hypertension is expected to propel the growth of the angiotensin receptor blockers (ARBs) market in the future. Hypertension, known as high blood pressure, is a condition characterized by persistently elevated pressure within blood vessels. Angiotensin receptor blockers (ARBs) are a class of medication commonly used to manage hypertension, primarily by relaxing and widening blood arteries to allow blood to flow more freely. This means a rise in hypertension cases among individuals will increase the demand for angiotensin receptor blockers. For instance, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 1.28 billion adults aged 30 to 79 globally suffer from hypertension, with the majority (two-thirds) residing in low- and middle-income countries. Furthermore, it is estimated that 46% of adults with hypertension are unaware of their condition. Therefore, the growing prevalence of hypertension is driving the growth of the angiotensin receptor blockers (ARBs) market.

What Segment Categories Are Covered In The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

What Trends Are Expected To Impact The Competitive Landscape Of The Angiotensin Receptor Blockers (ARBs) Market?

Key players in the angiotensin receptor blocker market are innovating advanced solutions, including angiotensin receptor neprilysin inhibitors, to broaden treatment possibilities and improve results for individuals with cardiovascular ailments. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of drugs employed in managing heart failure. Illustratively, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical firm, launched sacubitril + valsartan tablets, formulated specifically for the treatment of heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination is classified as an ARNI (angiotensin receptor neprilysin inhibitor). Sacubitril functions by strengthening the natriuretic peptide (NP) system, which helps reduce fluid overload and promotes the widening of blood vessels, while valsartan works by impeding the renin-angiotensin system (RAS) to decrease blood pressure and alleviate the heart’s workload. Together, these components effectively alleviate heart failure symptoms, reduce the risk of cardiovascular-related deaths, and lessen the probability of hospitalization due to heart failure. They are commercially available under the brand name Sacu V.

Which Leading Companies Dominate The Angiotensin Receptor Blockers (ARBs) Market Share?

Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

How Does The Angiotensin Receptor Blockers (ARBs) Market Perform Across Major Global Regions?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Angiotensin Receptor Blockers (ARBs) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2026, By The Business Research Company

Angiotensin Receptor Blockers Arbs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Anti Hypertensive Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795